A Phase I Investigation of MK5108 and MK5108 With Docetaxel in Patients With Advanced Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2018
At a glance
- Drugs Docetaxel; MK 5108
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 01 Dec 2015 According to an article published in the Investigational New Drugs, this study has been terminated early due to toxicities in Panel2 at MK-5108 doses below the anticipated PK exposure target.
- 01 Dec 2015 Results published in the Investigational New Drugs
- 27 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.